Obesity and metabolic syndrome: Pathological effects on the gastrointestinal tract

Histopathology

Volumn 68, Issue 5, 2016, Pages 630-640

  Feakins, Roger M ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Abdominal obesity; Carcinogenesis; Inflammation; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; CARCINOGEN; SOMATOMEDIN; VASCULOTROPIN; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; BARRETT ESOPHAGUS; BODY MASS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; GALLBLADDER CANCER; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY CELL; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PANCREAS TUMOR; PRECANCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ABDOMINAL OBESITY; ANIMAL; BLOOD; COMPLICATION; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HYPERINSULINISM; MOUSE; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; METABOLIC SYNDROME; MICE; OBESITY; OBESITY, ABDOMINAL; RISK FACTORS; TRIGLYCERIDES;

EID: 84955303840     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12907     Document Type: Review

References (91)

1. Cancer Research UK. The 20 most common causes of cancer deaths, UK. 2015. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/common-cancers-compared#heading-Zero
2. Cancer Research UK. The 10 most common causes of cancer death, world. 2015. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#heading-One
3. Finkelstein EA, Khavjou OA, Thompson H et al. Obesity and severe obesity forecasts through 2030. Am. J. Prev. Med. 2012; 42; 563-570.
4. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384; 766-781.
5. World Health Organization. Obesity and overweight. Fact sheet No. 311. World Health Organization Media Centre, 2015. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/
6. Centers for Disease Control and Prevention. Overweight and obesity. 2012. Available at: http://www.cdc.gov/obesity/adult/causes/index.html
7. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366; 1059-1062.
8. Kubo A, Cook MB, Shaheen NJ et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013; 62; 1684-1691.
9. Ashburn DD, Reed MJ. Gastrointestinal system and obesity. Crit. Care Clin. 2010; 26; 625-627.
10. Donohoe CL, Pidgeon GP, Lysaght J, Reynolds JV. Obesity and gastrointestinal cancer. Br. J. Surg. 2010; 97; 628-642.
11. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. 2005; 143; 199-211.
12. Singh S, Sharma AN, Murad MH et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2013; 11; 1399-1412.
13. Ryan AM, Duong M, Healy L et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol. 2011; 35; 309-319.
14. Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes. Rev. 2002; 3; 9-15.
15. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290; 66-72.
16. Abdallah J, Maradey-Romero C, Lewis S, Perzynski A, Fass R. The relationship between length of Barrett's oesophagus mucosa and body mass index. Aliment. Pharmacol. Ther. 2015; 41; 137-144.
17. Stein DJ, El-Serag HB, Kuczynski J, Kramer JR, Sampliner RE. The association of body mass index with Barrett's oesophagus. Aliment. Pharmacol. Ther. 2005; 22; 1005-1010.
18. Nelsen EM, Kirihara Y, Takahashi N et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2012; 10; 728-734.
19. Ryan AM, Healy LA, Power DG et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann. Surg. 2008; 247; 909-915.
20. Fujihara S, Mori H, Kobara H et al. Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol. Res. Pract. 2012; 2012; 483623.
21. Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS ONE 2013; 8; e52192.
22. Lindkvist B, Johansen D, Stocks T et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580, 000 subjects within the Me-Can project. BMC Cancer 2014; 14; 103.
23. Howard JM, Cathcart MC, Healy L et al. Leptin and adiponectin receptor expression in oesophageal cancer. Br. J. Surg. 2014; 101; 643-652.
24. McElholm AR, McKnight AJ, Patterson CC et al. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology 2010; 139; 204-212.
25. Ong J, Salomon J, te Morsche RH et al. Polymorphisms in the insulin-like growth factor axis are associated with gastrointestinal cancer. PLoS ONE 2014; 9; e90916.
26. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384; 755-765.
27. Onzi TR, d'Acampora AJ, de Araujo FM et al. Gastric histopathology in laparoscopic sleeve gastrectomy: pre- and post-operative comparison. Obes. Surg. 2014; 24; 371-376.
28. Mehta R, Birerdinc A, Younossi ZM. Host genetic variants in obesity-related nonalcoholic fatty liver disease. Clin. Liver Dis. 2014; 18; 249-267.
29. Baraille F, Guilmeau S, Postic C. Gastric bypass surgery in NASH: a major modulator of hepatic mitochondrial dysfunction. Gut 2015; 64; 524-526.
30. Sekikawa A, Fukui H, Maruo T et al. Gastric xanthelasma may be a warning sign for the presence of early gastric cancer. J. Gastroenterol. Hepatol. 2014; 29; 951-956.
31. Gencosmanoglu R, Sen-Oran E, Kurtkaya-Yapicier O, Tozun N. Xanthelasmas of the upper gastrointestinal tract. J. Gastroenterol. 2004; 39; 215-219.
32. Bosman FT, Carneiro F, Hruban RH, Theise ND eds. World Health Organization classification of tumours of the digestive system. 4th ed. Lyon: IARC, 2010.
33. Sobin LH, Gospodarowicz MK, Wittekind C; International Union against Cancer eds. TNM classification of malignant tumours, 7th ed. Chichester: Wiley-Blackwell, 2010.
34. Yang P, Zhou Y, Chen B et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur. J. Cancer 2009; 45; 2867-2873.
35. Lin XJ, Wang CP, Liu XD et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn. J. Clin. Oncol. 2014; 44; 783-791.
36. Tawfik OW, McGregor DH. Lipohyperplasia of the ileocecal valve. Am. J. Gastroenterol. 1992; 87; 82-87.
37. Lee CG, Lee JK, Kang YS et al. Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome. Am. J. Gastroenterol. 2015; 110; 310-319.
38. Boutros M, Maron D. Inflammatory bowel disease in the obese patient. Clin. Colon Rectal Surg. 2011; 24; 244-252.
39. Paik J, Fierce Y, Treuting PM, Brabb T, Maggio-Price L. High-fat diet-induced obesity exacerbates inflammatory bowel disease in genetically susceptible Mdr1a-/- male mice. J. Nutr. 2013; 143; 1240-1247.
40. Uko V, Vortia E, Achkar JP et al. Impact of abdominal visceral adipose tissue on disease outcome in pediatric Crohn's disease. Inflamm. Bowel Dis. 2014; 20; 2286-2291.
41. Mesa H, Drawz S, Dykoski R, Manivel JC. Morphometric measurement of submucosal thickness in areas of fat deposition in the terminal ileum and colonic sections, with correlation with body mass index, weight and age: a male autopsy study. Histopathology 2015; 67; 457-463.
42. Trabulo D, Ribeiro S, Martins C et al. Metabolic syndrome and colorectal neoplasms: an ominous association. World J. Gastroenterol. 2015; 21; 5320-5327.
43. Guiu B, Petit JM, Bonnetain F et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010; 59; 341-347.
44. Healy LA, Ryan AM, Sutton E et al. Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int. J. Colorectal Dis. 2010; 25; 1293-1299.
45. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107; 28-36.
46. Chiu HM, Lin JT, Shun CT et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin. Gastroenterol. Hepatol. 2007; 5; 221-229; quiz 141.
47. Johansen D, Stocks T, Jonsson H et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580, 000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol. Biomarkers Prev. 2010; 19; 2307-2317.
48. Scarpa M, Ruffolo C, Erroi F et al. Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case-control study. Anticancer Res. 2014; 34; 5735-5741.
49. Kim BC, Shin A, Hong CW et al. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control 2012; 23; 727-735.
50. Otake S, Takeda H, Suzuki Y et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin. Cancer Res. 2005; 11; 3642-3646.
51. Stein B, Anderson JC, Rajapakse R, Alpern ZA, Messina CR, Walker G. Body mass index as a predictor of colorectal neoplasia in ethnically diverse screening population. Dig. Dis. Sci. 2010; 55; 2945-2952.
52. East JE, Vieth M, Rex DK. Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance. Gut 2015; 64; 991-1000.
53. Holme O, Bretthauer M, Eide TJ et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut 2015; 64; 929-936.
54. Burnett-Hartman AN, Passarelli MN, Adams SV et al. Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am. J. Epidemiol. 2013; 177; 625-637.
55. Anderson JC, Rangasamy P, Rustagi T et al. Risk factors for sessile serrated adenomas. J. Clin. Gastroenterol. 2011; 45; 694-699.
56. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J. Clin. Gastroenterol. 2014; 48; 195-203.
57. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am. J. Gastroenterol. 2009; 104; 984-991.
58. Stolzenberg-Solomon RZ, Adams K, Leitzmann M et al. Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am. J. Epidemiol. 2008; 167; 586-597.
59. Lin CM, Huang HL, Chu FY et al. Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: a nationwide, population-based cohort study. PLoS ONE 2015; 10; e0125421.
60. Rebours V, Gaujoux S, d'Assignies G et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin. Cancer Res. 2015; 21; 3522-3528.
61. Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ. Metabolic syndrome and gallstone disease. World J. Gastroenterol. 2012; 18; 4215-4220.
62. Ahmed MH, Ali A. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first? Scand. J. Gastroenterol. 2014; 49; 521-527.
63. Yilmaz Y, Senates E, Yesil A, Ergelen R, Colak Y. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J. Diabetes Complications 2014; 28; 328-331.
64. Borena W, Stocks T, Jonsson H et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011; 22; 291-299.
65. Jing W, Jin G, Zhou X et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur. J. Cancer Prev. 2012; 21; 24-31.
66. Berger NA. Obesity-associated gastrointestinal tract cancer: from beginning to end. Cancer 2014; 120; 935-939.
67. Iyengar NM, Kochhar A, Morris PG et al. Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer 2014; 120; 983-991.
68. Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J. Gastroenterol. 2014; 20; 9026-9037.
69. Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J. Clin. Pathol. 2013; 66; 1033-1045.
70. Kalafateli M, Triantos CK, Nikolopoulou V, Burroughs A. Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review. Dig. Dis. Sci. 2012; 57; 2743-2754.
71. Westerhoff M, Tretiakova M, Hovan L, Miller J, Noffsinger A, Hart J. CD61, CD31, and CD34 improve diagnostic accuracy in gastric antral vascular ectasia and portal hypertensive gastropathy: an immunohistochemical and digital morphometric study. Am. J. Surg. Pathol. 2010; 34; 494-501.
72. Lash RH, Lauwers GY, Odze RD, Genta RM. Inflammatory disorders of the stomach. In Odze RD, Goldblum JR eds. Surgical pathology of the GI tract, liver, biliary tract and pancreas. 3rd ed. Philadelphia, PA: Saunders Elsevier, 2015; 352-401.
73. Liu Z, Brooks RS, Ciappio ED et al. Diet-induced obesity elevates colonic TNF-alpha in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J. Nutr. Biochem. 2012; 23; 1207-1213.
74. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 2005; 92; 2076-2083.
75. Max JB, Limburg PJ, Ogunseitan A et al. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: no association with incident colorectal cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol. Biomarkers Prev. 2008; 17; 1832-1834.
76. Doyle SL, Donohoe CL, Finn SP et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am. J. Gastroenterol. 2012; 107; 196-204.
77. Parekh N, Guffanti G, Lin Y, Ochs-Balcom HM, Makarem N, Hayes R. Insulin receptor variants and obesity-related cancers in the Framingham Heart Study. Cancer Causes Control 2015; 26; 1189-1195.
78. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006; 147; 4505-4516.
79. Padidar S, Farquharson AJ, Williams LM, Kearney R, Arthur JR, Drew JE. High-fat diet alters gene expression in the liver and colon: links to increased development of aberrant crypt foci. Dig. Dis. Sci. 2012; 57; 1866-1874.
80. Francois F, Roper J, Goodman AJ et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008; 57; 16-24.
81. Kendall BJ, Macdonald GA, Hayward NK et al. Leptin and the risk of Barrett's oesophagus. Gut 2008; 57; 448-454.
82. Rubenstein JH, Dahlkemper A, Kao JY et al. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am. J. Gastroenterol. 2008; 103; 1358-1364.
83. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br. J. Surg. 2010; 97; 1020-1027.
84. Donohoe CL, O'Farrell NJ, Doyle SL, Reynolds JV. The role of obesity in gastrointestinal cancer: evidence and opinion. Therap. Adv. Gastroenterol. 2014; 7; 38-50.
85. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res. 2013; 19; 6074-6083.
86. Day SD, Enos RT, McClellan JL, Steiner JL, Velazquez KT, Murphy EA. Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer. Cytokine 2013; 64; 454-462.
87. Wasan HS, Novelli M, Bee J, Bodmer WF. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl Acad. Sci. USA 1997; 94; 3308-3313.
88. Baltgalvis KA, Berger FG, Pena MM, Davis JM, Carson JA. The interaction of a high-fat diet and regular moderate intensity exercise on intestinal polyp development in Apc Min/+ mice. Cancer Prev. Res. 2009; 2; 641-649.
89. Newmark HL, Lipkin M, Maheshwari N. Colonic hyperplasia and hyperproliferation induced by a nutritional stress diet with four components of Western-style diet. J. Natl Cancer Inst. 1990; 82; 491-496.
90. Fryer E, Roberts IS, Sheppard MN, Verrill C. Postmortem examination in the morbidly obese. Histopathology 2014; 64; 200-210.
91. National Cancer Institute. Obesity and cancer risk. 2012. Available at: http://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet